Lactate dehydrogenase is the Achilles' heel of Lyme disease bacterium Borreliella burgdorferi.

IF 5.1 1区 生物学 Q1 MICROBIOLOGY
mBio Pub Date : 2025-04-09 Epub Date: 2025-03-20 DOI:10.1128/mbio.03728-24
Ching Wooen Sze, Michael J Lynch, Kai Zhang, David B Neau, Steven E Ealick, Brian R Crane, Chunhao Li
{"title":"Lactate dehydrogenase is the Achilles' heel of Lyme disease bacterium <i>Borreliella burgdorferi</i>.","authors":"Ching Wooen Sze, Michael J Lynch, Kai Zhang, David B Neau, Steven E Ealick, Brian R Crane, Chunhao Li","doi":"10.1128/mbio.03728-24","DOIUrl":null,"url":null,"abstract":"<p><p>As a zoonotic pathogen, the Lyme disease bacterium <i>Borreliella burgdorferi</i> has evolved unique metabolic pathways, some of which are specific and essential for its survival and thus present as ideal targets for developing new therapeutics. <i>B. burgdorferi</i> dispenses with the use of thiamin as a cofactor and relies on lactate dehydrogenase (BbLDH) to convert pyruvate to lactate for balancing NADH/NAD<sup>+</sup> ratios. This report first demonstrates that BbLDH is a canonical LDH with some unique biochemical and structural features. A loss-of-function study then reveals that BbLDH is essential for <i>B. burgdorferi</i> survival and infectivity, highlighting its therapeutic potential. Drug screening identifies four previously unknown LDH inhibitors with minimal cytotoxicity, two of which inhibit <i>B. burgdorferi</i> growth. This study provides mechanistic insights into the function of BbLDH in the pathophysiology of <i>B. burgdorferi</i> and lays the groundwork for developing genus-specific metabolic inhibitors against <i>B. burgdorferi</i> and potentially other tick-borne pathogens as well.</p><p><strong>Importance: </strong>Lyme disease (LD) is the most commonly reported tick-borne illness in the U.S. and Europe, and its geographic distribution is continuously expanding worldwide. Though early LD can be treated with antibiotics, chronic LD is recalcitrant to antibiotic treatments and thus requires multiple courses of antibiotic therapy. Currently, there are no human vaccines nor prophylactic antibiotics to prevent LD. As the causative agent of LD, <i>Borreliella burgdorferi</i> has evolved unique metabolic pathways, some of which are specific and essential for its survival and thus present as ideal targets for developing new therapeutics. By using an approach of genetics, biochemistry, structural biology, drug screening, and animal models, this report provides evidence that lactate dehydrogenase can be a potential target for developing genus-specific metabolic inhibitors against <i>B. burgdorferi</i> and potentially other tick-borne pathogens as well.</p>","PeriodicalId":18315,"journal":{"name":"mBio","volume":" ","pages":"e0372824"},"PeriodicalIF":5.1000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"mBio","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1128/mbio.03728-24","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

As a zoonotic pathogen, the Lyme disease bacterium Borreliella burgdorferi has evolved unique metabolic pathways, some of which are specific and essential for its survival and thus present as ideal targets for developing new therapeutics. B. burgdorferi dispenses with the use of thiamin as a cofactor and relies on lactate dehydrogenase (BbLDH) to convert pyruvate to lactate for balancing NADH/NAD+ ratios. This report first demonstrates that BbLDH is a canonical LDH with some unique biochemical and structural features. A loss-of-function study then reveals that BbLDH is essential for B. burgdorferi survival and infectivity, highlighting its therapeutic potential. Drug screening identifies four previously unknown LDH inhibitors with minimal cytotoxicity, two of which inhibit B. burgdorferi growth. This study provides mechanistic insights into the function of BbLDH in the pathophysiology of B. burgdorferi and lays the groundwork for developing genus-specific metabolic inhibitors against B. burgdorferi and potentially other tick-borne pathogens as well.

Importance: Lyme disease (LD) is the most commonly reported tick-borne illness in the U.S. and Europe, and its geographic distribution is continuously expanding worldwide. Though early LD can be treated with antibiotics, chronic LD is recalcitrant to antibiotic treatments and thus requires multiple courses of antibiotic therapy. Currently, there are no human vaccines nor prophylactic antibiotics to prevent LD. As the causative agent of LD, Borreliella burgdorferi has evolved unique metabolic pathways, some of which are specific and essential for its survival and thus present as ideal targets for developing new therapeutics. By using an approach of genetics, biochemistry, structural biology, drug screening, and animal models, this report provides evidence that lactate dehydrogenase can be a potential target for developing genus-specific metabolic inhibitors against B. burgdorferi and potentially other tick-borne pathogens as well.

乳酸脱氢酶是莱姆病细菌伯氏疏螺旋体的致命弱点。
作为一种人畜共患病原体,莱姆病细菌伯氏疏螺旋体已经进化出独特的代谢途径,其中一些是其生存所必需的特异性代谢途径,因此是开发新疗法的理想靶点。伯氏疏螺旋体不使用硫胺素作为辅助因子,依靠乳酸脱氢酶(BbLDH)将丙酮酸转化为乳酸,以平衡NADH/NAD+比率。本报告首先证明了BbLDH是一种典型的LDH,具有一些独特的生化和结构特征。一项功能缺失研究揭示了BbLDH对伯氏疏螺旋体的生存和传染性至关重要,突出了其治疗潜力。药物筛选鉴定出四种以前未知的LDH抑制剂,具有最小的细胞毒性,其中两种抑制伯氏疏螺旋体的生长。该研究为BbLDH在伯氏疏螺旋体病理生理中的功能提供了机制见解,并为开发针对伯氏疏螺旋体和其他潜在蜱传病原体的属特异性代谢抑制剂奠定了基础。重要性:莱姆病(LD)是美国和欧洲最常见的蜱传疾病,其地理分布在全球范围内不断扩大。虽然早期LD可以用抗生素治疗,但慢性LD对抗生素治疗难以抵抗,因此需要多个疗程的抗生素治疗。目前,没有人类疫苗或预防性抗生素来预防LD。作为LD的病原体,伯氏疏螺旋体已经进化出独特的代谢途径,其中一些是特异性的,对其生存至关重要,因此是开发新疗法的理想靶点。通过使用遗传学、生物化学、结构生物学、药物筛选和动物模型的方法,本报告提供了证据,证明乳酸脱氢酶可以作为开发针对伯氏疏螺旋体和其他潜在蜱传病原体的属特异性代谢抑制剂的潜在靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
mBio
mBio MICROBIOLOGY-
CiteScore
10.50
自引率
3.10%
发文量
762
审稿时长
1 months
期刊介绍: mBio® is ASM''s first broad-scope, online-only, open access journal. mBio offers streamlined review and publication of the best research in microbiology and allied fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信